Top View
- Epidermal Growth Factor Receptor Mutation Mediates Cross- Resistance to Panitumumab and Cetuximab in Gastrointestinal Cancer
- PATIENT FACT SHEET (Rituxan and Mabthera)
- Brentuximab Vedotin in Combination with Rituximab, Cyclophosphamide
- Abstract #630 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: the Orcharrd Study (OMB110928)
- Randomised Controlled Trial Comparing Ofatumumab to Rituximab
- Arzerra® (Ofatumumab) (Intravenous) -E- Document Number: MODA-0469 Last Review Date: 05/03/2021 Date of Origin: 06/2019 Dates Reviewed: 06/2019, 05/2020, 05/2021
- A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab As Frontline Therapy for Patients with Lymphomas Associated with Immunosuppression
- Ofatumumab Exhibits Enhanced in Vitro and in Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma Matthew J
- Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, Or Pancreatic Cancer: an Open-Label, Multicenter, Phase I/II Trial
- Zevalin, INN-Ibritumomab Tiuxetan
- Impact of the Subcutaneous Formulations of Trastuzumab And
- Y90 Ibritumomab Tiuxetan and I131 Tositumomab
- BEXXAR (Tositumomab and Iodine I 131 Tositumomab) Label
- Ibritumomab Tiuxetan (Interim Monograph)
- Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma J
- Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/ Cmet Bispecific
- 761150Orig1s000
- And Trastuzumab (Herceptin) Using Hyaluronidase
- Extravasation
- Brentuximab Vedotin and Diffuse Large B-Cell Lymphoma
- Rituximab Hypersensitivity Reactions and Tolerance of Ofatumumab Therapy
- Alemtuzumab: What Is the Secret to Safe Therapy?
- Oncology Medications Policy (1403)
- 11510B ZEV Patient Brochure R25v4 FIN.Indd
- Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR)
- Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment MAURIEN D
- FDA Drug Label
- Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer
- Combining CD47 Blockade with Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance
- Efficacy and Safety of Gemtuzumab Ozogamicin in Patients with CD33
- Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
- Use of Monoclonal Antibodies in Oncology
- 90Y Ibritumomab Tiuxetan
- Rituximab), Chimeric Antibody RELATED PRODUCTS
- 90Y-Ibritumomab Tiuxetan in the Treatment of Relapsed Or Refractory B-Cell Non-Hodgkin’S Lymphoma*
- June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
- Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal
- PDF of Antibody News
- Monoclonal Antibodies As Therapeutic Agents in Oncology and Antibody Gene Therapy
- Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
- Palliative Treatment of Malignant Ascites: Profile of Catumaxomab
- RITUXIMAB (Rituxan)
- BEXXAR (Tositumomab and Iodine I 131 Tositumomab)
- Management Guidelines for the Use of Alemtuzumab in Chronic Lymphocytic Leukemia
- Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology
- Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid Leukemia in the Non-Hematopoietic Stem Cell Transplant Setting
- DRUG NAME: Trastuzumab
- Brentuximab-Rituximab for Relapsed/Refractory Classical
- Lenalidomide Can Be Safely Combined with Chlorambucil and Rituximab In
- RITUXAN Prescribing Information
- Monoclonal Antibodies in Cancer Therapy
- Pharmaceutical Pipeline – Key Events in 2020*
- Rituximab) Injection, for Intravenous Use Achieved Disease Control with Induction Treatment, in Combination with Initial U.S
- Rituximab for Non-Oncology Indications – (5108)
- Effective Relief of Malignant Ascites in Patients with Advanced Ovarian
- Alemtuzumab (Campath-1H) in the Treatment of Chronic Lymphocytic Leukemia
- Treatment with Alemtuzumab Or Rituximab After Fingolimod Withdrawal in Relapsing–Remitting Multiple Sclerosis Is Effective and Safe
- Rituximab in Neurological Disease: Patient Information Sheet
- Immunotherapy of Recurrent B-Cell Malignancies After Allo-SCT with Bi20 (FBTA05), a Trifunctional Anti-CD3 Â Anti-CD20 Antibody and Donor Lymphocyte Infusion
- Update on the Rational Use of Tositumomab and Iodine-131 Tositumomab Radioimmunotherapy for the Treatment of Non-Hodgkin’S Lymphoma
- Radioimmunotherapy
- Publication Agenda CHMP 07-10 December 2020
- Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/Cmet Bispecific
- Highlights in Lymphoma from the 2017 American Society of Clinical
- Tositumomab and 131I Therapy in Non-Hodgkin's Lymphoma
- For Health Professionals Who Care for Cancer Patients